Is Ketamine a Psychedelic Drug?

Is ketamine a psychedelic drug?

The short answer is that ketamine is best classified as a dissociative anesthetic, not a classic psychedelic. Classic psychedelics such as psilocybin, LSD, and mescaline work primarily by activating a specific serotonin receptor. Ketamine does something different, so pharmacologically it sits in its own category.

That said, at the lower, sub-anesthetic doses used for mental health, ketamine can produce altered perception, a sense of detachment from the body, and dream-like experiences that feel psychedelic to many people. For that reason, researchers sometimes call it an atypical or non-classic psychedelic. So the honest answer is nuanced: it is not a classic psychedelic by mechanism, but it can create psychedelic-like effects.

What kind of drug ketamine actually is

Ketamine was developed in the 1960s as an anesthetic and is still widely used for anesthesia and pain, including in emergency medicine and pediatrics, because it relieves pain and induces a trance-like state without shutting down breathing the way some anesthetics do. In the United States it is a Schedule III controlled substance, reflecting an accepted medical use alongside a potential for misuse.

The term dissociative refers to the characteristic experience it produces: a feeling of being disconnected from your body, surroundings, or sense of self. Other dissociative drugs include PCP and dextromethorphan. Ketamine's more recent claim to fame is its rapid antidepressant effect, which can appear within hours, in contrast to standard antidepressants that take weeks.

How ketamine works in the brain

Ketamine's primary action is blocking the NMDA receptor, a docking site for the neurotransmitter glutamate, which is the brain's main excitatory signal. By blocking NMDA receptors on certain neurons, ketamine sets off a chain reaction that ends up increasing glutamate signaling elsewhere, particularly at receptors called AMPA receptors.

That surge is thought to trigger the release of growth factors like BDNF and to activate pathways that promote synaptogenesis, the formation of new connections between neurons. Many researchers believe this rapid boost in neuroplasticity, the brain's ability to rewire itself, is what underlies ketamine's fast antidepressant effect. This glutamate-based mechanism is completely different from the serotonin-receptor activation behind classic psychedelics.

Ketamine vs classic psychedelics

Lining ketamine up against classic psychedelics makes the differences concrete. They feel loosely similar to users at times, but they are distinct drugs with distinct biology and legal status.

• Mechanism: ketamine blocks NMDA (glutamate) receptors; classic psychedelics activate the 5-HT2A serotonin receptor.
• Drug type: ketamine is a dissociative anesthetic; psilocybin and LSD are serotonergic psychedelics.
• Experience: ketamine causes dissociation and detachment; classic psychedelics cause vivid visual and perceptual changes.
• Legal status: ketamine is Schedule III with accepted medical uses; psilocybin and LSD are Schedule I federally.
• Medical use: an esketamine nasal spray is FDA-approved for depression; classic psychedelics remain investigational in the U.S.
• Duration: ketamine's effects are relatively short, often under an hour or two; LSD can last many hours.

Ketamine and esketamine for depression

Ketamine's antidepressant potential has driven two parallel tracks. The first is intravenous ketamine given off-label in clinics for treatment-resistant depression, which is not FDA-approved for that use but is supported by a growing body of research. The second is esketamine, the S-molecule of ketamine, sold as the nasal spray Spravato.

The FDA first approved esketamine in 2019 for treatment-resistant depression when used together with an oral antidepressant, and later for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior. In January 2025 the FDA approved Spravato as a standalone monotherapy for treatment-resistant depression, the first time a drug of its kind was cleared to be used on its own for that condition. Because of risks including sedation, dissociation, and potential for misuse, Spravato is available only through a restricted REMS program and must be given in a certified healthcare setting with monitoring afterward.

What a ketamine experience feels like

At the low doses used for depression, people often describe feeling detached from their body, a floating or dream-like sensation, altered sense of time, and sometimes mild visual distortions. Some find it pleasant and insightful, while others find the dissociation unsettling, which is one reason clinical settings include support and monitoring.

These effects are temporary and typically fade within an hour or two of a treatment session. The antidepressant benefit, when it occurs, can outlast the immediate experience, which is why treatment is usually given as a series of sessions rather than a single dose.

Risks and why supervision matters

Ketamine is not risk-free. Short-term, it can raise blood pressure and heart rate, cause nausea, and produce disorientation, which is why blood pressure is monitored during clinical use. Used recreationally and repeatedly at high doses, it carries risks of bladder damage, cognitive problems, and psychological dependence.

This gap between supervised medical use and unsupervised recreational use is the whole point of the caution. In a clinic, dose, setting, and monitoring are controlled, and treatment is paired with mental health care. On the street, none of that applies, and the same drug becomes considerably more dangerous. If you are considering ketamine for depression, it should be through a licensed provider who can assess whether it fits your situation.